Skip to content

Study · Randomized controlled trial · n = 38 · 2009

5 results

[Effectiveness of cerebrolysin in hypertensive supratentorial intracranial hemorrhages: results of a randomized triple blind placebo-controled study].

Maksimova MIu, Briukhov VV, Timerbaeva SL, Kistenev BA, Rebrova OIu, Suslina ZA

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2009Cited by 1 (Europe PMC)

PMID19156082 (opens in a new tab)PepBankPUB-19156082
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In patients with small hypertensive supratentorial intracranial hemorrhages, Cerebrolysin showed good tolerability without specific adverse-event data.

    In plain wordsIn patients with small hypertensive intracranial hemorrhages, Cerebrolysin showed good tolerability without specific adverse-event data.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableTreatment tolerability
    Study

    n = 38

    Outcome group
    Adverse events · Whole body
    Studied dose
    30 ml · intravenous · 14 daysAs given in this study (human).

    Source sentences

    Summary
    High effectiveness and good tolerability of the treatment was shown.
    1 context sentence
    Summary · context
    Cerebrolysin was administered to 38 patients with small hypertensive supratentorial intracranial hemorrhages.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with hypertensive intracranial hemorrhages, total NIHSS scores differed significantly between Cerebrolysin and placebo at treatment end; direction was not reported.

    In plain wordsIn patients with hypertensive intracranial hemorrhages, NIHSS scores differed significantly between Cerebrolysin and placebo; direction was not reported.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedTotal NIHSS score
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 ml · intravenous · 14 daysAs given in this study (human).

    Source sentences

    Summary
    In the end of treatment, groups receiving cerebrolysin or placebo were statistically significant differed by the total NIHSS score, Bartel index and the Rankin's modified scale.
    1 context sentence
    Summary · context
    Cerebrolysin was administered to 38 patients with small hypertensive supratentorial intracranial hemorrhages.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with hypertensive intracranial hemorrhages, Bartel index scores differed significantly between Cerebrolysin and placebo at treatment end; direction was not reported.

    In plain wordsIn patients with hypertensive intracranial hemorrhages, Bartel index scores differed significantly between Cerebrolysin and placebo; direction was not reported.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedBartel index
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    30 ml · intravenous · 14 daysAs given in this study (human).

    Source sentences

    Summary
    In the end of treatment, groups receiving cerebrolysin or placebo were statistically significant differed by the total NIHSS score, Bartel index and the Rankin's modified scale.
    1 context sentence
    Summary · context
    Cerebrolysin was administered to 38 patients with small hypertensive supratentorial intracranial hemorrhages.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with hypertensive intracranial hemorrhages, modified Rankin scores differed significantly between Cerebrolysin and placebo at treatment end; direction was not reported.

    In plain wordsIn patients with hypertensive intracranial hemorrhages, modified Rankin scores differed significantly between Cerebrolysin and placebo; direction was not reported.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedModified Rankin scale
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    30 ml · intravenous · 14 daysAs given in this study (human).

    Source sentences

    Summary
    In the end of treatment, groups receiving cerebrolysin or placebo were statistically significant differed by the total NIHSS score, Bartel index and the Rankin's modified scale.
    1 context sentence
    Summary · context
    Cerebrolysin was administered to 38 patients with small hypertensive supratentorial intracranial hemorrhages.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with hypertensive intracranial hemorrhages, Cerebrolysin treatment was associated with a trend toward decreased intracranial hemorrhage volume.

    In plain wordsIn patients with hypertensive intracranial hemorrhages, Cerebrolysin treatment showed a trend toward decreased hemorrhage volume.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseIntracranial hemorrhage volume
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 ml · intravenous · 14 daysAs given in this study (human).

    Source sentences

    Summary
    Moreover, a trend to the decrease of intracranial hemorrhage volume was observed in patients treated with cerebrolysin.
    1 context sentence
    Summary · context
    Cerebrolysin was administered to 38 patients with small hypertensive supratentorial intracranial hemorrhages.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.